Want to see JP:4890 full AI Analyst Report?
Top Page
Tsubota Laboratory Incorporated
(4890)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥290.00
▼(-14.71% Downside)
Action:Reiterated
Date:07/25/26
The score is held back primarily by weak financial performance, driven by the 2026 revenue collapse, large losses, and sustained cash burn despite a low-debt balance sheet. Technicals provide only modest support with improving short-term signals but a still-negative long-term trend. Valuation is also pressured because the company is currently loss-making and offers no stated dividend yield.
Positive Factors
Conservative Capital Structure
Low leverage and substantial equity provide a meaningful financial cushion while operations fluctuate. This structure reduces dependence on debt financing, limits interest-related pressure, and preserves flexibility to stabilize the business or fund ophthalmology-related development.
Negative Factors
Severe Revenue Contraction
An 85.3% revenue collapse materially weakens the company’s commercial base and makes near-term earnings recovery dependent on rebuilding demand or commercialization. Such a sharp contraction also reduces the ability to absorb fixed costs and undermines the visibility of future operating scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Capital Structure
Low leverage and substantial equity provide a meaningful financial cushion while operations fluctuate. This structure reduces dependence on debt financing, limits interest-related pressure, and preserves flexibility to stabilize the business or fund ophthalmology-related development.
Read all positive factors
Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.87B
Dividend YieldN/A
Average Volume (3M)46.24K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth-71.21%
EPS Growth-485.42%
CountryJP
Employees22
SectorHealthcare
Sector Strength45
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)-26.90
Shares Outstanding25,969,738
10 Day Avg. Volume46,230
30 Day Avg. Volume46,243
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tsubota Laboratory Incorporated Business Overview & Revenue Model
Company Description
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and...
How the Company Makes Money
The company primarily makes money by commercializing ophthalmology-related offerings, which typically includes monetization from product and/or service sales tied to eye-care solutions and potentially revenues associated with research and developm...
Tsubota Laboratory Incorporated Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
73
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.58M | 200.02M | 1.36B | 673.53M | 954.69M | 640.92M |
| Gross Profit | 148.27M | 131.57M | 1.15B | -9.48M | 686.83M | 528.76M |
| EBITDA | -720.42M | -765.24M | 262.46M | -609.24M | 206.22M | 173.87M |
| Net Income | -693.63M | -761.82M | 205.77M | -641.32M | 90.18M | 153.32M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.32B | 2.50B | 2.30B | 2.67B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 699.26M | 969.85M | 1.54B | 1.88B | 2.16B | 1.17B |
| Total Debt | 63.64M | 69.21M | 90.38M | 116.90M | 139.34M | 223.82M |
| Total Liabilities | 578.57M | 454.92M | 915.85M | 927.93M | 722.59M | 873.44M |
| Stockholders Equity | 733.83M | 863.86M | 1.59B | 1.37B | 1.95B | 744.35M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -586.61M | -331.75M | -313.35M | -15.27M | 582.69M |
| Operating Cash Flow | 0.00 | -577.83M | -317.75M | -301.35M | 28.49M | 654.91M |
| Investing Cash Flow | 0.00 | -8.41M | -14.55M | -12.00M | -54.03M | -72.23M |
| Financing Cash Flow | 0.00 | 17.23M | -12.25M | 35.74M | 1.01B | -18.53M |
Tsubota Laboratory Incorporated Technical Analysis
Neutral
340.00
Price Trends
259.00
Positive
261.47
Positive
295.10
Negative
Market Momentum
11.69
Negative
62.07
Neutral
80.93
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Neutral. The current price of 340 is above the 20-day moving average (MA) of 284.75, above the 50-day MA of 259.00, and above the 200-day MA of 295.10, indicating a neutral trend. The MACD of 11.69 indicates Negative momentum. The RSI at 62.07 is Neutral, neither overbought nor oversold. The STOCH value of 80.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4890.
Tsubota Laboratory Incorporated Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥435.66B | 13.85 | 11.15% | 3.53% | 4.32% | 0.18% | |
69 Neutral | ¥543.27B | 16.88 | ― | 1.23% | 8.72% | 3.45% | |
64 Neutral | ¥1.04T | 18.02 | 7.67% | 2.04% | ― | ― | |
62 Neutral | ¥516.88B | 15.70 | 10.75% | 1.91% | 12.20% | -25.42% | |
54 Neutral | ¥403.30B | 23.80 | ― | 0.36% | 13.04% | -0.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥7.87B | -11.26 | ― | ― | -71.21% | -485.42% |
* Healthcare Sector Average
JP:4890
Tsubota Laboratory Incorporated
286.00
-72.00
-20.11%
JP:9989
Sundrug Co
3,731.00
-763.53
-16.99%
JP:7649
Sugi Holdings Co
1,323.00
-594.35
-31.00%
JP:3391
TSURUHA Holdings
2,341.00
-166.38
-6.64%
JP:3349
COSMOS Pharmaceutical Corporation
6,818.00
-2,092.43
-23.48%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,132.00
176.11
4.45%
Tsubota Laboratory Incorporated Corporate Events
Tsubota Laboratory Narrows Quarterly Loss as Revenue Surges and Eyes Full-Year Profit
Aug 13, 2026
Tsubota Laboratory reported a sharp increase in first-quarter revenue to ¥215 million, up more than eightfold year on year, while still posting a net loss of ¥134 million, which narrowed from the prior-year period. The company’s eq...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.